Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6773138 | 1.00 | SLC6A4 (0.41) | SLC6A4SLC6A3SLC6A2CYP1A2CYP2D6 | |
| SCHEMBL6767977 | 0.88 | KDM4E (0.43) | CYP1A2CYP2D6CYP2C9CYP2C19HTT | |
| SCHEMBL6767974 | 0.88 | KDM4E (0.43) | CYP1A2CYP2D6CYP2C9CYP2C19HTT | |
| SCHEMBL6771313 | 0.87 | CYP19A1 (0.41) | CYP1A2CYP2D6CYP2C9CYP2C19HTT | |
| SCHEMBL6772031 | 0.87 | CYP19A1 (0.41) | CYP1A2CYP2D6CYP2C9CYP2C19HTT | |
| SCHEMBL6771317 | 0.87 | CYP19A1 (0.41) | CYP1A2CYP2D6CYP2C9CYP2C19HTT | |
| SCHEMBL6768953 | 0.87 | MEN1 (0.48) | HTT | |
| SCHEMBL6768951 | 0.87 | MEN1 (0.48) | HTT | |
| SCHEMBL6771299 | 0.86 | ALDH1A1 (0.47) | CYP2C19 | |
| SCHEMBL6771297 | 0.86 | ALDH1A1 (0.47) | CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784167-B2 | TREATING OSTEOPOROSIS, OSTEOPENIA, OVARIAN CANCER, BREAST CANCER, ENDOMETRIAL CANCER, ENDOMETRIOSIS, PROSTATE CANCER, ACNE, ANDROGEN-DEPENDENT HAIR LOSS, NON-INSULIN-DEPENDENT DIABETES MELLITUS, OR HYPERCHOLESTEROLEMIA. | BAYER PHARMACEUTICALS CORPORATION | 2004-08-31 | — | — | US | disclosed |
| EP-1326829-A2 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE-II INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030087952-A1 | 17-Beta-hydroxysteroid dehydrogenase-II inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2003-05-08 | — | — | US | disclosed |
| WO-2002026706-A2 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE-II INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087952-A1 | 17-Beta-hydroxysteroid dehydrogenase-II inhibitors | HSD3B1, HSD3B2, HSD17B1 | SLC6A4 1003/4885SLC6A3 1875/4885SLC6A2 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.